Mindset Pharma CEO James Lanthier told investors that the firm has 'covered an enormous amount of ground' by advancing its library of next-generation psychedelic compounds.
Lanthier says by the end of its fiscal year it brought its patent application total up to eight, and highlighted the results its seen from its new drug families, identifying four different families of next-generation drugs.